flow trial semaglutide nejm effects of on chronic kidney disease 🚨#FLOW: The most anticipated the year now published in @NEJM Effects of Semaglutide Semaglutide, Chronic Kidney Disease, and

GLP-1 medications such as semaglutide and tirzepatide (brand names Ozempic, Wegovy, Mounjaro, Zepbound) have emerged as breakthrough medications for promoting weight loss and managing Type 2 diabetes

Dietary modifications are often the first-line approach: Eat smaller, more frequent meals rather than large portions, as this reduces the burden on your slowed digestive system

Endocrinology (2011) 152(11):40729

The product is marketed as a "revolutionary" wearable alternative to injectable GLP-1 medications like Ozempic

The procedure itself will take just a couple of minutes

FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight, U.S